Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.'The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.'Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 28 February 2026
2023-06-21 12:32:00 Wednesday ET

Michael Sandel analyzes what money cannot buy in stark contrast to the free market ideology of capitalism. Michael Sandel (2013) What money
2018-06-25 12:43:00 Monday ET

Apple and Samsung are the archrivals for the title of the world's top smart phone maker. The recent patent lawsuit settlement between Apple and Samsung
2017-08-01 09:40:00 Tuesday ET

In American states, all of the Top 4 richest people are self-made billionaires: Bill Gates in Washington, Warren Buffett in Nebraska, Michael Bloomberg in N
2022-02-22 09:30:00 Tuesday ET

The global asset management industry is central to modern capitalism. Mutual funds, pension funds, sovereign wealth funds, endowment trusts, and asset ma
2018-03-21 06:32:00 Wednesday ET

Fed Chair Jerome Powell increases the neutral interest rate to a range of 1.5% to 1.75% in his debut post-FOMC press conference. The Federal Reserve raises
2018-02-27 09:35:00 Tuesday ET

Fed's new chairman Jerome Powell testifies before Congress for the first time. He vows to prevent price instability for U.S. consumers, firms, and finan